Eicosanoid Transcellular Biosynthesis: From Cell-Cell Interactions to in Vivo Tissue Responses
Open Access
- 1 September 2006
- journal article
- review article
- Published by Elsevier in Pharmacological Reviews
- Vol. 58 (3) , 375-388
- https://doi.org/10.1124/pr.58.3.8
Abstract
The biosynthesis of the biologically active metabolites of arachidonic acid involves a number of enzymes that are differentially expressed in cells. Prostaglandins and thromboxanes are derived from the chemically unstable prostaglandin (PG) H2 intermediate synthesized by PGH synthases (cyclooxygenase-1/2) and leukotrienes from chemically unstable leukotriene A4 by 5-lipoxygenase. Additional enzymes transform these reactive intermediates to a variety of chemical structures known collectively as the lipid mediators. Although some cells have the complete cassette of enzymes required for the production of biolog-ically active prostaglandins and leukotrienes, the actual biosynthetic events often are a result of cell-cell interaction and a transfer of these chemically reactive intermediates, PGH2 and leukotriene A4, between cells. This process has come to be known as transcellular biosynthesis of eicosanoids and requires a donor cell to synthesize and release one component of the biosynthetic cascade and a second, accessory cell to take up that intermediate and process each into the final biologically active product. This review focuses on the evidence for transcellular biosynthetic events for prostaglandins, leukotrienes, and lipoxins occurring during cell-cell interactions. Evidence for arachidonic acid serving as a transcellular biosynthetic intermediate is presented. Experiments for transcellular events taking place in vivo that reveal the true complexity of eicosanoid biosynthesis within tissues are also reviewed.Keywords
This publication has 54 references indexed in Scilit:
- Leukotriene A4 hydrolase and leukotriene C4 synthase activities in human chondrocytes: Transcellular biosynthesis of leukotrienes during granulocyte-chondrocyte interactionArthritis & Rheumatism, 1998
- Pharmacological characterization of the cysteinyl-leukotriene antagonists CGP 45715A (iralukast) and CGP 57698 in human airwaysin vitroBritish Journal of Pharmacology, 1998
- Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles.Journal of Clinical Investigation, 1997
- Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions.Proceedings of the National Academy of Sciences, 1995
- Enhanced excretion of urinary leukotriene E4 in coronary artery disease and after coronary artery bypass surgeryCoronary Artery Disease, 1993
- Time-dependent utilization of platelet arachidonic acid by the neutrophil in formation of 5-lipoxygenase products in platelet-neutrophil co-incubationsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1992
- Adhesion promotes transcellular leukotriene biosynthesis during neutrophil-glomerular endothelial cell interactions: Inhibition by antibodies against CD18 and L-selectinBiochemical and Biophysical Research Communications, 1992
- Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation.Circulation, 1992
- Human endothelial cells stimulate leukotriene synthesis and convert granulocyte released leukotriene A4 into leukotrienes B4, C4, D4 and E4European Journal of Biochemistry, 1988
- Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregationProstaglandins, 1976